KLDO (Kaleido Biosciences) EBIT: $-87.45 Mil (TTM As of Dec. 2021)


What is Kaleido Biosciences EBIT?

Kaleido Biosciences KLDO EBIT is $-87.45 Mil as of Dec. 2021.

Kaleido Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2021 was $-19.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was $-87.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kaleido Biosciences's annualized ROC % for the quarter that ended in Dec. 2021 was -378.16%. Kaleido Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -1,203.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was 521.28%.

Kaleido Biosciences  (OTCPK:KLDO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kaleido Biosciences's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

ROC % (Q: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2021 ) + Invested Capital (Q: Dec. 2021 ))/ count )
=-78.796 * ( 1 - 0% )/( (16.521 + 25.152)/ 2 )
=-78.796/20.8365
=-378.16 %

where

Invested Capital(Q: Sep. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=67.804 - 12.24 - ( 55.657 - max(0, 19.261 - 58.304+55.657))
=16.521

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=50.137 - 12.356 - ( 38.474 - max(0, 29.682 - 42.311+38.474))
=25.152

Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Kaleido Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2021  Q: Dec. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-78.228/( ( (7.339 + max(-10.23, 0)) + (5.665 + max(-9.701, 0)) )/ 2 )
=-78.228/( ( 7.339 + 5.665 )/ 2 )
=-78.228/6.502
=-1,203.14 %

where Working Capital is:

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.647) - (12.24 + 0.15 + 0.487)
=-10.23

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.837) - (12.356 + 0.828 + 0.354)
=-9.701

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2021 )
=-87.45/-16.776
=521.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences EBIT Related Terms

Kaleido Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences EBIT Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBIT
Get a 7-Day Free Trial -27.12 -60.74 -85.35 -78.82 -87.45

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.30 -22.33 -23.18 -22.38 -19.56

KLDO vs NPTX, GSTC, BZYR: EBIT Comparison

For the Biotechnology subindustry, Kaleido Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaleido Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's EV-to-EBIT falls into.


Kaleido Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-87.45 Mil mean?
Kaleido Biosciences (KLDO) has a EBIT of $-87.45 Mil as of Dec. 2021. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kaleido Biosciences.
Is Kaleido Biosciences' EBIT too high?
Kaleido Biosciences' current EBIT is $-87.45 Mil.
How does Kaleido Biosciences' EBIT compare to NPTX and GSTC?
Kaleido Biosciences' EBIT of $-87.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kaleido Biosciences. Kaleido Biosciences's current EBIT is $-87.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current EBIT of $-87.45 Mil. The current EBIT is $-87.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current EBIT is $-87.45 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.